[en] This article summarises a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the International Congress of the European Respiratory Society in 2023. Translational and clinical studies focused on the whole spectrum of ILDs, from (ultra)rare ILDs to sarcoidosis, ILDs associated with connective tissue disease and idiopathic pulmonary fibrosis. The main topics of the 2023 Congress presentations were improving the diagnostic process of ILDs, better prediction of disease course and investigation of novel treatment options.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Fabbri, Laura; Margaret Turner Warwick Centre for Fibrosing Lung Diseases, NHLI, Imperial College, London, UK ; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK
Guiot, Julien ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Vermant, Marie; Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
Miądlikowska, Ewa; Department of Pneumology, Medical University of Lodz, Lodz, Poland
Estrella, Deborah; Hospital das Clínicas, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
Wijsenbeek, Marlies S; Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
Wuyts, Wim ; Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
Bargagli, Elena; Respiratory Diseases Unit, Department Medical Sciences, Surgery and Neurological Sciences, Siena University, Siena, Italy
Froidure, Antoine; Pulmonology Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium
Spagnolo, Paolo; Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy
Veltkamp, Marcel; ILD Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands ; Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands
Molina-Molina, Maria; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, CIBERES, Barcelona, Spain
McCarthy, Cormac ; UCD School of Medicine, Education and Research Centre, St Vincent's University Hospital, Dublin, Ireland
Antoniou, Katerina ; Laboratory of Molecular and Cellular Pneumonology, Dept of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, Greece
Kreuter, Michael; Mainz Center for Pulmonary Medicine, Department of Pneumology, ZfT, Mainz University Medical Center and Department of Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany
Moor, Catharina C ; Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
Guler SA, Cuevas-Ocaña S, Nasser M, et al. ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Res 2022; 8: 00640-2021.
Karampitsakos T, Diep PP, Loth DW, et al. ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Res 2023; 9: 00584-2022.
Justet A, Ravaglia C, Zhao A, et al. Spatial transcriptomic analysis reveals similar gene expression patterns in the long COVID and IPF lungs. Eur Respir J 2023; 62: Suppl. 67, OA4198.
Bell J, Eyres M, Davies E, et al. Defining and modelling the fibrotic niche in lung fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA4197.
Khan P, Blumer S, Savic S, et al. A 3D organoid model mimicking honeycomb cysts in idiopathic pulmonary fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA4204.
Bozza E, Bozzini S, Bagnera C, et al. Hyaluronic acid decorated-liposome loaded with imatinib: an in vitro study as targeted drug delivery system for lung fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA4201.
Rosas L, Vanegas N-D, Riley M, et al. STING inhibitor ameliorates senescence via inhibiting cGAS-STING pathway in idiopathic pulmonary fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA4199.
Petersen AG, Bousamaki J, Andreasen LJ, et al. Therapeutic effects of ALK5i on pulmonary function and fibrosis in a high-fat diet + bleomycin-induced and spirometry-confirmed mouse model of IPF. Eur Respir J 2023; 62: Suppl. 67, OA4202.
Vanegas N, Rosas L, Garcia PA, et al. SMAC mimetic as potential anti-fibrotic therapy in an in vivo model of bleomycin-induced pulmonary fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA4203.
Ainola M, Hollmén M, Laaka A, et al. KIF15 missense variant is associated with a distinct prognostic clinical phenotype in idiopathic pulmonary fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA2579.
Furukawa T, Kondoh Y, Oyama S, et al. Nationwide all ILD registry with central MDD in Japan; providing multidisciplinary ILD diagnoses (PROMISE) study. Eur Respir J 2023; 62: Suppl. 67, OA1424.
Trushell-Pottinger D, Holbourn A, Nandakumar K, et al. Experience of making early interstitial lung disease diagnosis from patients taking part in UK national pilot lung screening programme. Eur Respir J 2023; 62: Suppl. 67, OA1425.
van der Sar IG, Wijsenbeek MS, Braunstahl GJ, et al. Electronic nose technology differentiates interstitial lung diseases from other chronic respiratory diseases. Eur Respir J 2023; 62: Suppl. 67, OA1427.
Kim J, Das P, Ma S-F, et al. Buccal microbiome and survival in idiopathic pulmonary fibrosis: CleanUP-IPF. Eur Respir J 2023; 62: Suppl. 67, OA1432.
Guler SA M, Cox D-C, Durand G, et al. The clinical frailty scale is associated with progression of fibrotic interstitial lung disease – a multicentre cohort study. Eur Respir J 2023; 62: Suppl. 67, OA1430.
Im Y, Yoo H. Development and validation of a nomogram for predicting pulmonary complications after curative resection in idiopathic pulmonary fibrosis patients with early stage lung cancer. Eur Respir J 2023; 62: Suppl. 67, OA1428.
Nakshbandi G, Moor CC, Veltkamp M, et al. Home spirometry in regular care for patients with pulmonary fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA3283.
Kellogg D, Nambiar A, Justice J, et al. Post hoc pooled analyses of open-label and randomized controlled trials of senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA2583.
Arora P, Lickliter J, Richardson B, et al. A novel interleukin-11 receptor antibody, LASN01 is well tolerated and demonstrates target engagement in phase 1. Eur Respir J 2023; 62: Suppl. 67, OA2581.
Wuyts WA, Valenzuela C, Jenkins G, et al. Safety, tolerability and antifibrotic activity of bexotegrast: phase 2a INTEGRIS-IPF study (NCT04396756). Eur Respir J 2023; 62: Suppl. 67, OA1423.
Glaspole I, Cai D, Chambers D. Safety and efficacy study of ACT001 in IPF and fILD patients. Eur Respir J 2023; 62: Suppl. 67, OA2585.
Borie R, De Fontbrune FS, Jouneau S, et al. Efficacy and safety of DANAZOL for pulmonary fibrosis associated with telomere related gene mutation. Eur Respir J 2023; 62: Suppl. 67, OA2580.
West A, Lawrence A, Bao H, et al. Nebulised pirfenidone in idiopathic pulmonary fibrosis (IPF): first look at FVC data. Eur Respir J 2023; 62: Suppl. 67, OA2582.
Corte T, Behr J, Cottin V, et al. BMS-986278 for progressive pulmonary fibrosis (PPF): results from a phase 2 randomised controlled trial. Eur Respir J 2023; 62: Suppl. 67, RCT800.
Molyneaux P, Wu Z, Spencer LG, et al. Morphine sulfate for the treatment of cough in idiopathic pulmonary fibrosis: the PAciFy cough randomised clinical trial. Eur Respir J 2023; 62: Suppl. 67, OA4195.
Myall K, West A, Martinovic J, et al. Treatment of obstructive sleep apnoea in patients with interstitial lung disease improves quality of life and survival. Eur Respir J 2023; 62: Suppl. 67, OA2586.
Dhooria S, Sehgal IS, Agarwal R, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). Eur Respir J 2023; 62: 2300198.
Kinnersley N, Chandrasekaran A, Ramesh P, et al. Therapeutic doses of efzofitimod significantly improve multiple pulmonary sarcoidosis efficacy measures. Eur Respir J 2023; 62: Suppl. 67, PA1744.
Bermudo Peloche G, Del Río B, Vicens-Zygmunt V, et al. Pirfenidone in post-covid19 pulmonary fibrosis (FIBRO-COVID): phase-II randomised clinical trial (NCT04607928). Eur Respir J 2023; 62: Suppl. 67, OA3282.
Harari SA, Elia D, Caminati A, et al. Nintedanib for lymphangioleiomyomatosis: an open-label phase II study. Eur Respir J 2023; 62: Suppl. 67, OA3274.
Trapnell B, Arumugam P, Carey B, et al. Preclinical studies supporting a first-in-human trial of pulmonary macrophage transplantation therapy of CSF2RA-associated PAP. Eur Respir J 2023; 62: Suppl. 67, OA3276.
Bonella F, Wasserstein M, Giugliani R, et al. Reversal of interstitial lung disease after olipudase alfa enzyme replacement therapy in adults with acid sphingomyelinase deficiency. Eur Respir J 2023; 62: Suppl. 67, OA3281.
George P, Benvenuti G, Rennison-Jones C, et al. Novel e-Lung CT biomarkers combine to provide higher prognostic discrimination than FVC in patients with non-IPF fibrotic interstitial lung disease. Eur Respir J 2023; 62: Suppl. 67, OA855.
Guiot J, Gester F, Henket M, et al. AI-based quantification of ILD and pulmonary vasculature in a retrospective SSc-ILD cohort correlates with pulmonary function test: a perspective from the PROFILE.net ERS Clinical Research Collaboration. Eur Respir J 2023; 62: Suppl. 67, OA853.
Zielonka J, Li N, Wang Z, et al. Skin transcriptomes link severity of skin involvement and lung function impairment in systemic sclerosis. Eur Respir J 2023; 62: Suppl. 67, OA856.
Hoffmann-Vold AM, Petelytska L, Fretheim H, et al. Progression of interstitial lung disease in systemic sclerosis does not predict further progression. Eur Respir J 2023; 62: Suppl. 67, OA857.
Moraes MML, Telini WM, Batah SS, et al. Dendritic cells as a potential new tool in predicting patient’s survival in airway-centered interstitial fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA851.
Moor K, Van Der Sar IG, Wijsenbeek MS. Electronic nose technology detects connective tissue disease-associated interstitial lung disease. Eur Respir J 2023; 62: Suppl. 67, OA852.
Solomon J, Leavy OC, Kawano-Dourado L, et al. Rheumatoid arthritis and idiopathic pulmonary fibrosis: a bidirectional Mendelian randomisation study. Eur Respir J 2023; 62: Suppl. 67, OA858.
Novais Bastos H, Santos R, Cardoso CG, et al. Unveiling common molecular pathways linked to ILDs with progressive fibrosing phenotype: the role of MUC5B promoter variants. Eur Respir J 2023; 62: Suppl. 67, OA854.
Cameli P, Caffarelli C, Al Refaie A, et al. Evaluation of bone mineral density and fracture risk in sarcoidosis population. Eur Respir J 2023; 62: Suppl. 67, PA1747.
Møller J, Rejnmark L, Bendstrup E. Change in bone mineral density in Danish patients with sarcoidosis. Eur Respir J 2023; 62: Suppl. 67, PA2228.
Kreuter M, Buschulte K, Höger P, et al. How informed are patients with pulmonary sarcoidosis about their disease? Eur Respir J 2023; 62: Suppl. 67, PA2218.
Fanetti M, D’Alessandro M, Gangi S, et al. T follicular helper cell subsets in sarcoidosis patients: a comparison between three anatomical compartment. Eur Respir J 2023; 62: Suppl. 67, PA2219.
Ventura V, Cassai L, Pordon E, et al. CD56dimCD16bright in peripheral blood, lung lymph node and bronchoalveolar lavage from sarcoidosis patients. Eur Respir J 2023; 62: Suppl. 67, PA2225.
Messina M, D’Alessandro M, Gangi S, et al. T helper and T cytotoxic cells subsets in peripheral, alveolar and lymph nodes of sarcoidosis patients. Eur Respir J 2023; 62: Suppl. 67, PA2221.
Hatem O, Jarvis H, Thwaites R, et al. RESPISAM: type 1 inflammation biomarkers from bronchial mucosal lining fluid in parenchymal versus nodal sarcoidosis. Eur Respir J 2023; 62: Suppl. 67, PA2223.
Lederer C, Guth K, Bohács A, et al. New diagnostic approaches for lymphangioleiomyomatosis (LAM). Eur Respir J 2023; 62: Suppl. 67, OA3278.
Krymskaya V, Obraztsova K, Mukhitov A, et al. Alveolar fibroblast activation and epithelial injury/repair in pulmonary lymphangioleiomyomatosis (LAM). Eur Respir J 2023; 62: Suppl. 67, OA3279.
Diesler R, Legendre M, Si-Mohamed S, et al. Phenotypic characterisation of interstitial lung disease associated with mutations in SFTPC and ABCA3 in adults. Eur Respir J 2023; 62: Suppl. 67, OA3280.
Ishii H, Tazawa R, Handa T, et al. Exploring the prognosis and pathogenesis of secondary pulmonary alveolar proteinosis. Eur Respir J 2023; 62: Suppl. 67, OA3277.
Manali ED, Papiris SA, Kallieri M, et al. Autoimmune pulmonary alveolar proteinosis (aPAP) in Greece: 20 years in progress. Eur Respir J 2023; 62: Suppl. 67, OA3275.
